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Abstract
Background: Given projected shortages of critical care capacity in public hospitals during the COVID-19 pandemic,
the South African government embarked on an initiative to purchase this capacity from private hospitals. In order
to inform purchasing decisions, we assessed the cost-effectiveness of intensive care management for admitted
COVID-19 patients across the public and private health systems in South Africa.
Methods: Using a modelling framework and health system perspective, costs and health outcomes of inpatient
management of severe and critical COVID-19 patients in (1) general ward and intensive care (GW + ICU) versus (2)
general ward only (GW) were assessed. Disability adjusted life years (DALYs) were evaluated and the cost per
admission in public and private sectors was determined. The model made use of four variables: mortality rates,
utilisation of inpatient days for each management approach, disability weights associated with severity of disease,
and the unit cost per general ward day and per ICU day in public and private hospitals. Unit costs were multiplied
by utilisation estimates to determine the cost per admission. DALYs were calculated as the sum of years of life lost
(YLL) and years lived with disability (YLD). An incremental cost-effectiveness ratio (ICER) - representing difference in
costs and health outcomes of the two management strategies - was compared to a cost-effectiveness threshold to
determine the value for money of expansion in ICU services during COVID-19 surges.
Results: A cost per admission of ZAR 75,127 was estimated for inpatient management of severe and critical COVID-
19 patients in GW as opposed to ZAR 103,030 in GW + ICU. DALYs were 1.48 and 1.10 in GW versus GW + ICU,
respectively. The ratio of difference in costs and health outcomes between the two management strategies
produced an ICER of ZAR 73,091 per DALY averted, a value above the cost-effectiveness threshold of ZAR 38,465.
Conclusions: Results indicated that purchasing ICU capacity from the private sector during COVID-19 surges may
not be a cost-effective investment. The ‘real time’, rapid, pragmatic, and transparent nature of this analysis
demonstrates an approach for evidence generation for decision making relating to the COVID-19 pandemic
response and South Africa’s wider priority setting agenda.
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Background
The COVID-19 pandemic has intensified demands on
the health care system and resulted in critical shortages
of resources (hospital beds, intensive care unit (ICU)
beds, ventilators, medical workforce), particularly in the
South African public sector. A major area of concern,
globally and in South Africa, was the sufficiency of ICU
capacity for the management of critically ill COVID-19
patients. Against an ICU bed availability of 3,318 (1,178
public and 2,140 private), the South African Portfolio
Committee on Health highlighted a shortfall in ICU beds
in the country; where the peak daily demand for ICU
beds was projected to be between 4,100 beds (optimistic
scenario) and 14,767 (pessimistic scenario) [1]. Based on
the expected progression of COVID-19 in South Africa
and expected utilisation rates of ICU in the management
of COVID-19, projections suggested insufficient supply
of ICU capacity in the public sector. Government
adopted a two-pronged strategy including (1) the adop-
tion of a lockdown strategy to flatten the curve in an ef-
fort to reduce the likelihood of demand exceeding the
available health care supply and (2) initiatives to pur-
chase critical bed capacity from the South African pri-
vate sector for use by public sector patients.
Intensive care services are very expensive and are one
of the largest drivers of hospital costs, even in public
hospitals where the cost per patient per ICU day has
been estimated at R22,700 [2]. Discovery Health, the lar-
gest private medical scheme in the country, at the time
reported that the average cost of all COVID-19 hospital
admissions across its members was R84,708. The average
cost of an ICU admission for its members was substan-
tially higher - at R169,525 - and these admissions were
also reported to have the “highest variation in cost”
[3]. While public sector ICU capacity was projected to
be limited, overprovision of ICU beds in the private sec-
tor was a key finding of the recent Competition Com-
mission Health Market Inquiry [4], presenting an
opportunity for government to purchase additional ser-
vices from private hospitals for use by public sector
dependent patients.
There are a range of health care interventions to man-
age the progression of the COVID-19 pandemic.
Amongst others, resources are required to carry out
education, screening, testing, isolation and contact tra-
cing programs, provision of personal protective equip-
ment (PPE) to health workers, treatment in general/high
care wards; and in the most critical cases, treatment in
ICU. Given the expected downturn in an already weak
economy [5] coupled with the increased demand for
government resources for economic relief and other
measures, the ability of government to commit add-
itional funding to a resource-constrained public health
sector is limited. Within this context, it is imperative
that available government resources are used fairly and
efficiently, and that the costs and effects of potential in-
terventions and approaches to care are assessed and
weighed against the opportunity costs of their required
investment. Traditional economic evaluations can be
time consuming with lengthy turnaround times. The
rapid pace at which the pandemic unfolded and the im-
perative it created for policy decisions to be made
quickly required the turnaround times for research and
analysis informing policy to be shortened substantially.
The objective of this study was to assess the cost-
effectiveness of ICU management for admitted COVID-
19 patients across the public and private health sector in
South Africa using a “real time”, pragmatic and transpar-
ent health economic modelling approach. The results of
this analysis can contribute towards evidence informed
policy making and planning during COVID-19 surges




MOSAIC, a health economic modelling collective estab-
lished to respond to the need for prompt policy guid-
ance for the South African response to COVID-19,
carried out this cost-utility/effectiveness analysis of ICU
care. The study was conducted using the principles of
the International Decision Support Initiative Reference
Case for economic evaluation [6]. It considers two gen-
eralised strategies for the inpatient management of se-
vere and critical COVID-19 patients: (1) general ward
and ICU management (GW + ICU): admitted patients
are managed in a combination of general wards and
ICU, with escalation to ICU based on established clinical
criteria for severity of disease; (2) general ward manage-
ment: admitted patients are managed in general wards
only. This approach enables an estimation of the added
value of ICU care in comparison to a general ward only
comparator. The latter is therefore a modelled “do noth-
ing” strategy that provides estimates of the outcomes
that could result from the severe rationing of ICU care
during surges in COVID-19 cases. Costs are expressed
as the cost per case admitted from the health systems
perspective, in 2020 South African Rand (ZAR), includ-
ing both public and private sector costs. Outcomes are
expressed as disability adjusted life years (DALYs) and
deaths. While the simple measures of “deaths avoided”
or “lives saved” are useful and easy to interpret, they
miss important treatment effects, such as improvements
in morbidity, and they cannot be used to make compre-
hensive assessments of value for money compared to
other treatment options in the health sector. In contrast,
representing the impact of interventions as disability-
adjusted life years (DALYs) averted allows consideration
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of health gains due to a reduction of both fatal and non-
fatal disease burden; one DALY can be thought of as
one lost year of healthy life. Incremental cost-
effectiveness ratios (ICERs) are calculated as the differ-
ence in costs divided by the difference in health benefits
of the treatment strategies, and are compared to a cost
effectiveness threshold (CET) derived from an estimate
of the marginal productivity of the public health system
in South Africa [7]. If the ICER is lower than the CET
then the marginal opportunity cost of the treatment
strategy (in terms of lost health) is expected to be lower
than the health benefits of the treatment strategy, indi-
cating that the treatment strategy is likely to represent a
cost-effective use of limited resources [6]. The time hori-
zon for the analysis was from admission to discharge or
death; while estimates of ongoing morbidity post dis-
charge were included within DALYs, no costs after dis-
charge were estimated. The years of life lost (YLL) from
COVID-19 mortality was informed by a secondary actu-
arial analysis and was not discounted.
Decision analytic model
A decision analytic modelling framework was imple-
mented in TreeAge Pro 2020 (TreeAge Software, Inc,
Williams- town, Massachusetts, USA) and exported to
Microsoft Excel for ease of stakeholder engagement and
review, as depicted in Fig. 1. The model and accompany-
ing user guide are available at https://doi.org/10.25375/
uct.12382706.
Within the model, patients are ‘randomized’ to each
treatment strategy (GW+ ICU versus GW); and on ad-
mission (to public or private hospitals), patients are
modelled as severe or critical. Depending on these fac-
tors, patients incur admission costs and accumulate
health outcomes as they transition to one of two absorb-
ing states: recover or die. Recovered patients receive a
morbidity loss over the duration of their disease and
thereafter are assumed to return to their pre-COVID-19
health state, while morbidity as well as YLLs are cap-
tured for those dying. Further details of these costs and
outcomes are provided within Table 1.
Model variables
The model rests on 4 different types of variables: mortal-
ity rates based on severity of illness (i.e. severe versus
critical) and approach towards disease management (i.e.
GW+ ICU versus GW); utilisation data including pro-
portions of hospitalized individuals that are critical ver-
sus severe, proportion managed in public versus private
hospitals and length of stay data for each patient type
and management approach; unit costs per inpatient day
in general wards and intensive care units specific to pub-
lic and private hospitals; and DALY data including YLL,
years lived with disability (YLD) and disability weights
(DWs). A brief overview of each type of data is provided
below. Evidence relating to disease progression and ef-
fectiveness of interventions has rapidly changed over the
Fig. 1 Decision analytic model structure
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course of the COVID-19 pandemic. The parameters
used in the model represent best available evidence as at
end of May 2020.
Mortality rates
Mortality rates were extracted from the literature. A sys-
tematic search for articles published in English between
01/01/2019 and 30/05/2020 in Medline/PubMed was
completed using the terms: “COVID-19” OR “novel cor-
onavirus” OR “SARS-COV-2” OR COVID-19 OR 2019-
COV OR “2019 novel coronavirus” AND “clinical char-
acteristics” OR “clinical features” OR “clinical outcomes”
AND “death” OR “mortality”. Additional relevant articles
were sourced through a manual search of bibliographies
of included articles.
As outlined in Fig. 2, the results of the initial search
were screened by title and abstract. The full texts of po-
tentially relevant articles were retrieved and assessed for
inclusion. When articles reported information from the
same study sites but at two different time periods, only
the articles with the updated statistics were included in
this analysis. A total of sixteen observational studies
(cross-sectional or cohort) and case series that reported
the outcomes of hospitalized COVID-19 patients were
included within quantitative synthesis. Average weighted
estimates of the case fatality rate among ICU patients
Table 1 Costs and outcomes in each model state
Health
state
Cost per health state Transition outcome to
recovered
Transition outcome to dead
Severe
patients
Public / private sector cost per hospitalisation in general ward
for severe patients
Disability weight for severe
patients applied over duration
of 1.5 months
Disability weight for severe patients
applied over duration of 0.5 months;
Years of Life Lost
Critical
patients
Public / private sector cost per hospitalisation in general ward
and ICU for critical patients (GW + ICU model) or general ward
only (GW model)
Disability weight for critical
patients applied over duration
of 2 months
Disability weight for critical patients
applied over duration of 0.5 months;
Years of Life Lost
Fig. 2 Flow diagram of search strategy and study selection
Cleary et al. BMC Health Services Research           (2021) 21:82 Page 4 of 10
and non-ICU patients/patients dying in general ward
were calculated using the formula: Deaths/(Deaths +
Recovered).
Utilisation
Utilisation includes the proportions of hospitalized indi-
viduals that are critical versus severe and length of stay
data for each patient type by type of management
(utilization of ICU days by critical patients, utilization of
general ward days for severe patients, and for critical pa-
tients before/after ICU). These variables were extracted
from seven articles [8–16] identified in the above-
mentioned systematic search. Average weighted esti-
mates for each variable were calculated. Finally, the pro-
portion of patients using public versus private hospitals
was based on the proportion of South Africans with pri-
vate medical scheme membership [17].
Unit costs
The model considers the costs of inpatient care in public
and private hospitals through the inclusion of unit costs
per general ward day and per ICU day. These are multi-
plied against the abovementioned length of stay esti-
mates to generate a cost per admission. Private sector
unit costs are based on the tariff rates in the “Guidelines
on Public Private Collaboration in Response to COVID-
19” published by the Department of Health [18]. Public
sector unit costs were calculated using the Health Sys-
tems Trust District Health Barometer (12th Edition –
2016/17) datafile [19] which provides hospital-level esti-
mates of expenditure per patient day equivalent (PDE)
for all categories of public sector hospitals. These costs
were inflated to 2020 prices using the Consumer Price
Index [20] and a weighted average unit cost was calcu-
lated through weighting unit costs by the percentage of
useable beds across levels of care. Because the HST-
DHB data do not provide an estimate of the unit cost
per ICU day, we estimated this by inflating the average
weighted cost by the cost differential between ICU and
general ward tariffs in the private sector.
DALYs
DALYs are calculated through the summation of YLL
and YLD. YLL were informed by a South African actuar-
ial analysis that utilised age- and co-morbidity adjusted
mortality rates observed internationally and applied
these to the South African population [21]. This resulted
in an average estimate of 5.4 YLL per death in South Af-
rica. A wide range on this parameter was tested in sensi-
tivity analysis to reflect the relative uncertainty
associated with transferring international mortality data
to the South African context. At the time of analysis,
duration of morbidity was unknown for COVID-19;
assumptions were therefore made for these parameters.
Disability weights for severe/critical COVID-19 patients
were based on relevant estimates for similar conditions
from the 2017 Global Burden of Disease study [22].
Sensitivity analysis
Simple sensitivity analyses were run across all variables
to assess the impact of changes on the ICER. Where
possible, ranges for sensitivity analysis were based on
upper and lower confidence intervals or interquartile
ranges found within the systematic literature review. For
the remaining variables, a 50 % increase/decrease was
implemented, except for where this would move the
variable out of feasible range (e.g. mortality rates can
only fall within the range 0–1). Thereafter, threshold
analyses were run to estimate the percentage change in
variables that would render ICU cost-effective, using the
published South African CET [7] as the cut-off for this
determination. Finally, an additional scenario was mod-
elled in order to incorporate the effect of administration
of the steroid dexamethasone. This analysis entailed the
inclusion of the cost of a course of dexamethasone (ZAR
160.85 for twenty 4 mg vials as per 2020 Essential Medi-
cines List price), as well as rate ratio reductions in
deaths from ICU (0.65) or from general wards (0.80) as
provided in estimates from a United Kingdom based
randomized controlled trial [23].
Ethical considerations
This is a modelled cost-effectiveness/utility analysis




Table 2 provides a summary of the variables used in the
model, together with the ranges on variables used for sen-
sitivity analysis. As is shown, the unit cost per inpatient
day in GW was estimated at approximately ZAR 3,700 in
public hospitals versus ZAR 5,300 in private; while ICU
care was estimated at approximately ZAR 18,000 and
ZAR 25,000 in public versus private respectively. In terms
of utilisation, the literature review provided an estimate of
21.25 inpatient days in general wards for severe patients;
1 day in general ward plus 8.8 days in ICU for critical pa-
tients; and that 21 % of admitted patients would be critical
and in need of ICU. Mortality estimates suggested that
11 % of severe patients treated in general wards and 54 %
of critical patients treated in ICU would die.
As highlighted in the table, there are two key un-
knowns for this economic evaluation that both apply to
the GW strategy. The first is the proportion of critical
patients that would die if they did not have access to
ICU. This unknown has been based on the high value
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found in the meta-analysis for critical patients dying
from ICU (88 % mortality) with ranges for sensitivity
analysis including 70 % and 100 % mortality. The other
unknown is the length of stay for these critical patients,
which is assumed to be the same as for critical patients
managed in ICU.
Other important unknowns include disability
weights for COVID-19, with the DW for severe
lower respiratory tract infection assumed for severe
COVID-19 patients and the DW for severe pneumo-
coniosis assumed for critical patients, as extracted
from the Global Burden of Disease study [22]. Dur-
ation of illness is assumed to be 0.5 months in those
dying, 1.5 months in severe patients and 2 months in
critical patients. Finally, YLL is based on inter-
national mortality rates per 100 000 population by
age and co-morbidity applied to the South African
demographic structure [21].







Method or assumption (range for sensitivity analysis) Reference or
source
Unit costs






Average weighted expenditure per patient day equivalent (±
50 %)
[19]






Average weighted expenditure per patient day equivalent
inflated using private tariff differential (± 50 %)
Assumption






Published tariff rates (± 50 %) [18]






Published tariff rates (± 50 %) [18]
Utilisation
LoS in general ward in severe
patients
21.25 7.25 43.00 Literature review (IQR) [11, 12]
LoS in ICU in critical patients 8.80 4.30 13.30 Literature review (IQR) [8–10, 13, 14]
LoS in general ward in critical
patients in absence of ICU
8.80 4.30 13.30 Assumed to be the same as critical patients treated in ICU Assumption
LoS in general ward in critical
patients before/after ICU
1.00 0.00 3.00 Literature review (IQR) [12]
Proportion needing ICU 0.21 0.05 0.50 Literature review (low and high value) [12–15, 24–27]
Proportion reliant on public health
system




Proportion of severe patients dying 0.11 0.00 0.13 Literature review (low and high value) [12, 14–16, 24]
Proportion of critical patients dying
from ICU
0.54 0.24 0.88 Literature review (low and high value) [8–10, 12–16,
24, 29, 30]
Proportion of critical patients dying
without access to ICU
0.88 0.70 1.00 Assumed high value on critical patients dying from ICU (-20 %;1) Assumption
DALYs
Disability weight in severe patients 0.13 0.09 0.19 Disability weight for severe lower respiratory tract infection (95 %
CI)
[22]
Disability weight in critical patients 0.41 0.27 0.56 Disability weight for severe pneumoconiosis (95 % CI) [22]
Duration of illness in severe
patients
0.13 0.06 0.19 1.5 months (± 50 %) Assumption
Duration of illness in critical
patients
0.17 0.08 0.25 2 months (± 50 %) Assumption
Duration of illness prior to death 0.04 0.02 0.06 0.5 months (± 50 %) Assumption
Years of life lost if dying from
COVID-19






Used to assess value for money; if ICER < CET intervention
potentially cost-effective
[7]
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Cost-effectiveness
Table 3 summarizes the cost-effectiveness results. As-
suming base case values across all variables, the model
produces a cost per admission of ZAR 75 127 versus
ZAR 103 030, deaths at 27 % versus 20 %, and DALYs at
1.48 versus 1.10 in the general ward versus GW+ ICU
strategy, respectively. The incremental cost-effectiveness
ratio is ZAR 73 091 per DALY averted or ZAR 390 798
per death averted. Taking into account the proportions
of admitted patients who are severe versus critical, the
general ward strategy requires 18.85 general ward days
per admission, while the GW+ ICU strategy requires 17
general ward days and 1.85 ICU days.
Sensitivity analysis
Sensitivity analyses were run on all variables with the
ranges for these analyses presented in Table 2. The tor-
nado diagram in Fig. 3 summarizes the results for the
seven analyses that generated the largest changes to the
ICER. All other analyses generated lower or negligible
changes in cost-effectiveness. To guide an interpretation
of these findings, ICERs are compared against the cost-
effectiveness threshold of ZAR 38,465 per DALY averted
[7]. This represents the marginal productivity of the
South African health system; interventions would need
to generate an ICER lower than or equivalent to this
value to be potentially cost-effective.
As is shown in Fig. 3, three analyses showed promise
for generating a cost-effective ICER for the GW+ ICU
strategy: (1) length of stay in ICU in critical patients
(shorter LoS improves cost-effectiveness); (2) cost per
ICU day (less costly services improves cost-
effectiveness); and (3) proportion of critical patients
dying from ICU (lower mortality improves cost-
effectiveness). Other important drivers of cost-
effectiveness include YLL (if more lost life years can be
averted, ICU becomes more cost-effective) and the out-
comes of critical patients managed in general wards
(poorer outcomes improves the relative benefits of ICU).
In effect, these analyses indicate that if ICU were less
costly (either through reduction in the unit cost or the
length of stay) or more effective (either through reduced
mortality or targeting the service towards patients with
higher potential years of life to lose), purchasing add-
itional intensive care from private hospitals would be
more likely to be a cost-effective use of government
resources.
The threshold analysis (Table 4) takes this one step
further to estimate the exact percent change in variables
needed to generate cost-effective ICERs. As is shown,
five threshold values were found. To render additional
purchasing of ICU cost-effective, we would need a 57 %
decrease in the proportion of critical patients dying from
ICU; 48 % decrease in the public sector cost per ICU
day; 38 % decrease in ICU length of stay; 179 % increase
in LoS in critical patients managed in general wards; or
89 % increase in YLL in those dying from COVID-19.
Finally, we conducted a scenario analysis on the im-
pact of dexamethasone on the cost-effectiveness of ICU
through the inclusion of the price of a course of dexa-
methasone and rate ratio reductions in mortality as pro-
vided from a UK based randomized control trial
[23]. The results from this scenario indicate a slightly
improved ICER of ZAR 70,400 per DALY averted for
the GW+ ICU strategy.
Discussion
Based on the evidence available at the time of analysis
(up to end of May 2020) and at base case values, this art-
icle presents the cost-effectiveness of alternative man-
agement strategies for admitted COVID-19 patients in
South African hospitals. The policy relevance of these
findings relates to decision-making during surges in
COVID-19 cases when hospital capacity becomes con-
strained and hard choices need to be made around the
rationing of care. During these surges, this analysis sug-
gests that it may not be cost-effective for government to
purchase additional ICU beds from private hospitals. In
addition, if public sector resources (such as staffing) are
severely constrained due to surges in COVID-19, the
analysis suggests that better returns will be achieved
through the provision of additional staffed and oper-
ational general ward beds within public hospitals. As
shown in sensitivity analyses, these findings are driven
by three key factors: (1) the high mortality in critical pa-
tients admitted to ICU; (2) the relatively low number of
years of life lost in those dying; and (3) the relatively
high cost of ICU services (which is a function of unit
cost and length of stay).
While intensive care is expensive, if it were effective at
preventing deaths in critically ill COVID-19 patients, it
would have generated more favourable results. However,
our meta-analysis of evidence from nine available studies
suggested that outcomes were poor [8–16, 24, 29, 30].
Table 3 Base case cost-effectiveness results (2020 ZAR)
Strategy Cost (ZAR) DALYs Deaths ICU Days Genl. Ward Days Incr. Cost per DALY Averted Incr. Cost per Death Averted
Genl. Ward 75 127 1.48 0.27 - 18.85
Genl. Ward + ICU 103 030 1.10 0.20 1.85 17.00 73 091 390 798
DALYs Disability adjusted life years, Genl. General, ICU Intensive care unit, Incr. Incremental
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The mortality rate for critically ill patients managed in
ICU was on average 54 % (range: 28 %-88 %) meaning
that for a substantial proportion of critical COVID-19
patients, admission to ICU was unlikely to be a life-
saving intervention. While the inclusion of dexametha-
sone improved the ICER results, it did not move the
ICER into the cost-effective range. That said, the dexa-
methasone scenario illustrates how the inclusion of new
technologies such as medicines could generate changes
in the economics of inpatient care for COVID-19.
Approaches to decision making in the face of resource
scarcities (also called “priority setting”) commonly in-
cludes four fundamental values or ethical principles
drawn from theories of distributive justice [31, 32]: (1)
“utilitarianism” - doing the greatest good for the greatest
number of people, either by saving the highest number
of lives and/or saving the largest number of life-years,
which is the basis of cost-effectiveness; (2) “egalitarian-
ism” – providing equal access or equal treatment for
equal need; (3) “rule of rescue” – providing urgent, life-
saving treatments irrespective of the cost; and (4) “des-
ert” - promoting and rewarding social usefulness
[33]. Based on utilitarian or egalitarian approaches, there
would be limited merit in government purchasing add-
itional ICU capacity from private hospitals. However,
justification for investing in ICU may be found through
the application of other ethical principles such as the
“rule of rescue”. The latter calls on society to respond to
the extreme risk faced by an identifiable individual, how-
ever it generally only holds when the numbers are small.
The difficulty to face with COVID-19 is that while many
of us align with a rule of rescue based response, the stark
realities of resource constraints call on us to acknow-
ledge that the allocation of government resources to
purchase ICU capacity from private hospitals would have
a high opportunity cost in terms of the competing uses
of those funds.
While the economic evaluation methodology can pro-
vide quantitative evidence to inform each of these ethical
principles, and hence is a key input to any consideration
Fig. 3 Tornado diagram summarizing simple sensitivity analyses








Proportion of critical patients dying from ICU
(pdeadICU)
0.54 0.23 -57 % 57 % decrease in ICU mortality renders ICU cost-effective
Cost per ICU day public (cICUpub) 17,845 9,227 -48 % 48 % decrease in cost per ICU day in public sector renders ICU
cost-effective
LoS in ICU in critical patients (uICU) 8.80 5.5 -38 % 38 % decrease in ICU length of stay renders ICU cost-effective
LoS in general ward in critical patients in
absence of ICU (uIPDcritical)
8.80 24.59 179 % 179 % increase in length of stay for critical patients managed in
general ward renders ICU cost-effective
Years of life lost if dying from COVID-19 (YLL) 5.40 10.21 89 % 89 % increase in YLL in those dying renders ICU cost-effective
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of distributive justice [34], experience globally suggests
that a multi-ethical framework is more likely to result in
a fairer allocation of resources. Moreover, because rea-
sonable people should be expected to disagree on the
relative merits of these ethical principles, priority setting
needs to be vested within procedural justice, a key aspect
of which is transparent deliberation [35]. Our real-time
and open access approach to modelling provides one ex-
ample of how such transparency can be facilitated.
There are a number of limitations to this study and
similar studies. The urgency to inform decision making
and restrictions on primary data collection necessitated
a reliance on secondary data while the ongoing emer-
gence of new information required flexibility in model
building. To address these concerns (1) a comprehensive
systematic review was carried out to ensure that all of
the available information was fed into the model and (2)
an open access modelling framework [36] with a user
guide [37] was developed to facilitate full exploration of
uncertainty through sensitivity analysis and to allow for
parameters to be quickly and easily updated as new in-
formation becomes available. A further limitation is that
this analysis is static in nature and does not provide pro-
jections of the total need for ICU or general ward beds
as the epidemic unfolds across South Africa during 2020
and 2021. The implication is that the findings are of
relevance during surges in COVID-19 when capacity is
breached, and hard choices need to be made regarding
the rationing of both general ward and ICU care. The
findings do not necessarily apply to COVID-19 ICU care
during times when COVID-19 admissions are
manageable.
Conclusions
This rapid analysis provided key evidence on the cost-
effectiveness of alternative management strategies in the
hospital care of critical and severe patients with COVID-
19 disease in the South African setting. It has shown that
ICU use for COVID-19 patients was unlikely to be cost-
effective on the margin, and therefore an expansion of
ICU capacity during COVID-19 surges through govern-
ment purchase of private services for use by public sector
patients (at current prices and evidence of effectiveness)
may not be the best use of limited health resources,
whether from utilitarian or egalitarian ethical perspectives.
There are few (if any) examples of decision analytic
modelling and cost effectiveness analysis being con-
ducted in “real time” to inform policy decisions in the
South African public health sector. The rapid, pragmatic
and transparent analysis employed by the MOSAIC
group demonstrates a potential approach for further evi-
dence generation for decisions relating to the COVID-19
pandemic response and South Africa’s wider priority set-
ting agenda.
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